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Authors’ reply In response to the first question, 
the smoking group included current smokers, 
while in the group with chronic obstructive pul‑ 
monary disease (COPD), we included patients 
with diagnosed COPD, in whom the inflammatory 
process had been maintained for many years due 
to previous or current exposure to tobacco smoke, 
and had been chronically treated with broncho‑ 
dilators or, additionally, with anti ‑inflammatory 
drugs.
Several previous studies reported the role of in‑ 
flammatory processes and their mechanisms in 
COPD.1 Not all smokers have developed a chron‑ 
ic inflammatory process in the airways, and even 
more so, not all have been diagnosed with COPD. 
However, active smokers seem to be more ex‑ 
posed to increased concentrations of oxidative 
stress markers than nonsmokers with long ‑term 
COPD, which may affect the mechanisms associat‑ 
ed with stent thrombosis and restenosis. The role 
of inflammation has also been demonstrated in 
patients with sarcopenia and COPD, who showed 
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a higher percentage of cardiovascular comorbid‑
ity and levels of systemic inflammatory mark‑
ers.2 Due to the lack of data on height in our da‑
tabase, we could not calculate body mass index; 
moreover, we did not perform bioelectrical im‑
pedance analysis and muscle handgrip strength 
measurements. 
However, in the overall group of patients, the 
mean weight was lower in the subgroup of pa‑
tients with COPD (P <0.001), without in‑stent 
thrombosis at baseline (P = 0.01), and without re‑
stenosis at baseline (P < 0.001). The mean weight 
was also lower in the subgroup of patients with 
COPD previously treated with percutaneous cor‑
onary intervention (P = 0.03). Contrary to the 
overall group, the mean weight was lower in pa‑
tients with in‑stent thrombosis (P = 0.001) and 
restenosis (P = 0.03) at baseline. This indicates 
that lower weight in patients with COPD is relat‑
ed to higher rate of in‑stent thrombosis and re‑
stenosis at baseline in the subgroup of patients 
previously treated with percutaneous coronary 
intervention.
Regarding the second question, the mecha‑
nisms of venous and arterial thrombosis seem 
to be different. Patients with COPD exacerba‑
tion showed a significantly increased risk of ve‑
nous thrombosis, which is mainly explained by 
a transient aggravation of inflammatory process‑
es, enhanced oxidative stress, and prothrombot‑
ic state including increased thrombin genera‑
tion.3 In contrast, the increased risk of arterial 
thrombosis seems to be more due to endothelial 
dysfunction and platelet hyperreactivity, which 
has been shown in patients with stable COPD.4 
Platelet activation was found to predict an ad‑
verse outcome in patients with stable coronary 
artery disease and to be related to recurrent car‑
diovascular events following percutaneous coro‑
nary intervention.5,6
In response to the third question, a number of 
published studies demonstrated poor compliance 
in patients with COPD, especially those who have 
difficulty quitting smoking.7 We also observed 
that smokers with COPD more often than non‑
smokers tend to stop pharmacological treatment 
prematurely after revascularization, and some‑
times they even do not take aspirin and statin, 
not to mention dual antiplatelet therapy. They 
also tend to discontinue the use of bronchodila‑
tors and return to them only in case of COPD ex‑
acerbation. Special care means, at least, a longer 
follow ‑up and more frequent visits. Moreover, 
patients should be encouraged to undergo regu‑
lar pulmonary checkups and to stop smoking if 
they have not done so already.
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